The BPC-157 and TB-500 (1:1) blend represents a highly synergistic combination of two well-characterised peptides frequently evaluated in cellular repair and migration assays. BPC-157, a synthetic pentadecapeptide derived from gastric juices, interacts directly with the nitric oxide synthase pathway to promote angiogenesis and cellular survival. Concurrently, TB-500, a synthetic fraction of Thymosin Beta-4, primarily binds to actin monomers, regulating cellular motility and cytoskeletal reorganisation. As a premium research chemical, UK laboratories utilise this specific blend to investigate complex tissue remodelling in vitro. Advanced peptide synthesis techniques ensure that both components maintain their structural integrity during experimental procedures. To preserve optimal molecular stability in aqueous environments, researchers must follow strict reconstitution protocols using Bacteriostatic Reconstitution Solution. Detailed structural data for these compounds is catalogued in PubChem, providing a robust foundation for ongoing biochemical analysis.
Public search data clusters around phrases like "healing" and "recovery" when discussing the BPC-157 and TB-500 blend. Current literature catalogues these terms as markers for cellular migration and angiogenesis observed in isolated lab experiments. Research trends focus on the synergistic effects of these two sequences in cell-free systems, not as a bodily protocol. Amino Peptides supplies this blend exclusively for controlled laboratory research.
- BPC-157 interacts with the endothelial nitric oxide synthase (eNOS) pathway, modulating nitric oxide generation in isolated vascular endothelial cell models.
- TB-500 (Thymosin Beta-4 fragment) acts as a primary actin-sequestering peptide, binding to G-actin monomers to regulate cytoskeletal dynamics in cell-free systems.
- Synergistic receptor engagement involves the upregulation of Vascular Endothelial Growth Factor (VEGF) receptors (VEGFR2) during controlled cellular migration experiments.
- Modulation of the focal adhesion kinase (FAK) and paxillin phosphorylation pathways, critical for directed cellular motility in fibroblast cultures.
- BPC-157 promotes the activation of the Early Growth Response 1 (EGR-1) transcription factor, stimulating extracellular matrix remodeling in isolated tenocyte models.
- TB-500 facilitates actin polymerization and depolymerization cycles by maintaining a dynamic pool of G-actin, essential for lamellipodia formation in migrating cells.
- The 1:1 blend accelerates the formation of vascular-like networks in two-dimensional endothelial cell cultures through synergistic eNOS and VEGFR2 signaling cascades.
- Inhibits the expression of pro-inflammatory cytokines such as TNF-alpha and IL-6 in lipopolysaccharide-stimulated macrophage models, demonstrating immunomodulatory potential in isolated cellular environments.
Technical Specifications
Variant Breakdown
- 10mg Vial: Contains a precise 1:1 ratio (5mg BPC-157 and 5mg TB-500), ideal for preliminary in vitro screening and short-term cellular assays.
- 20mg Vial: Provides a balanced 1:1 formulation (10mg of each peptide) suited for medium-scale laboratory investigations requiring consistent dosing over multiple well plates.
- 30mg Vial: Delivers a high-capacity 1:1 mixture (15mg of each peptide) designed for extensive, longitudinal biochemical studies and comprehensive receptor binding analyses.
Quality Assurance
- HPLC Verification: High-performance liquid chromatography ensures the blend achieves >99% purity, confirming the exact 1:1 molecular ratio without cross-contamination.
- Mass Spectrometry: Electrospray ionisation mass spectrometry (ESI-MS) validates the individual molecular weights of both BPC-157 and TB-500.
- Lyophilisation Protocol: Processed into a stable lyophilised solid under stringent vacuum conditions to prevent peptide degradation prior to reconstitution.
- Endotoxin Testing: Rigorous laboratory characterisation guarantees endotoxin levels remain below <0.5 EU/mg, preventing cellular toxicity in sensitive in vitro cultures.
Research Mechanism
- Nitric oxide synthase (NOS) activation by BPC-157, promoting endothelial cell migration and the formation of new blood vessels (angiogenesis) in cellular models.
- Upregulation of vascular endothelial growth factor (VEGF) and early growth response protein 1 (EGR-1) gene expression, facilitating extracellular matrix remodelling.
- Actin-sequestering properties of TB-500, which binds to G-actin monomers to prevent premature polymerisation into F-actin filaments, thereby enhancing cellular motility.
- Modulation of focal adhesion kinase (FAK) and paxillin by both peptides, leading to improved cellular adhesion and structural reorganisation in vitro.
- Synergistic interaction in cellular assays, where enhanced actin dynamics driven by TB-500 complement the increased angiogenic signalling initiated by BPC-157.
Reconstitution & Storage Data
| Vial Strength | Solvent Added | Resulting Concentration |
| 10mg | 1 mL Bacteriostatic Reconstitution Solution | 10.00 mg/mL |
| 10mg | 2 mL Bacteriostatic Reconstitution Solution | 5.00 mg/mL |
| 20mg | 1 mL Bacteriostatic Reconstitution Solution | 20.00 mg/mL |
| 20mg | 2 mL Bacteriostatic Reconstitution Solution | 10.00 mg/mL |
| 30mg | 1 mL Bacteriostatic Reconstitution Solution | 30.00 mg/mL |
| 30mg | 2 mL Bacteriostatic Reconstitution Solution | 15.00 mg/mL |
- Lyophilised (Powder): Store in a standard refrigerator (2-8°C) for up to 3 months. For long-term preservation, freeze at -20°C.
- Reconstituted (Liquid): Store at 2-8°C (Refrigerated).
Scientific References
Journal of Physiology and Pharmacology: "BPC 157 and Standard Angiogenic Growth Factors" View Study
Annals of the New York Academy of Sciences: "Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues" View Study
European Journal of Pharmacology: "BPC 157 and nitric oxide system" View Study
Vitamins and Hormones: "Thymosin beta4 and cell migration in vitro" View Study
Journal of Applied Physiology: "BPC 157 promotes the ex vivo outgrowth of tendon fibroblasts" View Study